AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US

AstraZeneca (AZN) announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rival Boehringer Ingelheim earlier this month.This cap would apply to all of AstraZeneca’s inhaled respiratory products, which include Airsupra, Bevespi Aerosphere, Breztri Aerosphere and Symbicort.However, the company plans not to start this until June 2024. The British drugmaker is one of the biggest sellers of inhalers in the United State ...